MediWound (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced the signing of an agreement granting COVALEO SA de CV exclusive rights to market and distribute NexoBrid in Mexico for the treatment of severe burns.
Severe burns are primarily treated at approximately 20 hospitals and burn centers in Mexico.
NexoBrid is an easy-to-use, topically-applied pharmaceutical product that removes dead or damaged tissue, known as eschar, in approximately four hours without harming the surrounding healthy tissue.
In addition to this agreement in Mexico, MediWound has executed exclusive distribution agreements for NexoBrid to treat severe burns in Argentina, Russia and South Korea.
"We are pleased to announce our second distribution agreement in the Latin America region and look forward to working with COVALEO to bring NexoBrid to patients across Mexico. COVALEO is known for its experience and expertise in the wound care field and already distributes several products in this market," stated Gal Cohen, President and Chief Executive Officer of MediWound.
NexoBrid is an easy-to-use, topically-applied product that removes dead or damaged tissue, known as eschar, in approximately four hours without harming the surrounding healthy tissues.
NexoBrid received marketing authorization from the European Medicines Agency for the removal of eschar in adults with deep partial and full-thickness thermal burns, and was commercially launched in Europe in December 2013.